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Non coding RNAs and Duchenne Muscular Dystrophy 1 
 2 
Abstract 3 
Purpose of review 4 
Non coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs 5 
(lncRNAs) modulate gene transcription or translation in response to environmental stressors 6 
and other stimuli. A role for ncRNAs in muscle pathologies has been demonstrated and 7 
further evidence suggests that ncRNAs also play a role in Duchenne Muscular Dystrophy 8 
(DMD). 9 
Key findings 10 
Studies investigating the differential expression of miRNAs in biological fluids between 11 
DMD patients, and models of dystrophin deficiency (the MDX mouse model, canine models 12 
of DMD) and controls have been published, as have their role in fibrosis. miRNA-1, -133a,b, 13 
and -206 are the most reported miRNAs, and have been implicated in myogenic 14 
differentiation, fibrosis, and regulation of utrophin and dystrophin translation. 15 
Overexpression of miR-486 slows down disease progression in the MDX mouse model. 16 
lncRNAs, such as hsa-lnc-31 and linc-MD1, are differentially expressed in DMD patients and 17 
may, in part, have a mechanism of action via targeting of miRNAs, such as miR-133b. 18 
Although many of these recent findings need to be confirmed, ncRNAs may prove to be 19 
useful as potential biomarkers of disease. However, their use as therapeutic targets in DMD 20 
remains unclear. 21 
Summary 22 
There may be a role for using circulating miRNAs as biomarkers of disease status. The use of 23 
ncRNAs as a therapeutic option for DMD remains to be determined. 24 
 25 
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Introduction 28 
Duchenne Muscular Dystrophy (DMD) is the most common muscular dystrophy affecting 29 
children. It is a severe X-linked neuromuscular disease caused by mutations in the dystrophin 30 
gene. DMD is characterized by a rapid progression of muscle degeneration that leads to the 31 
loss of ambulation and death within the second decade of life without medical intervention 32 
[1–3]. 33 
Dystrophin has a major structural role in muscle as it links the internal cytoskeleton to the 34 
extracellular matrix. The amino-terminus of dystrophin binds to F-actin and the carboxyl 35 
terminus to the dystrophin-associated protein complex (DAPC) at the sarcolemma [4]. The 36 
DAPC includes the dystroglycans, sarcoglycans, dystrobrevin and syntrophin, and mutations 37 
in any of these components cause autosomally inherited muscular dystrophies [3]. The DAPC 38 
is destabilized when dystrophin is absent, which results in diminished levels of its composite 39 
proteins [5]. This, in turn, leads to progressive fibre damage and membrane leakage. 40 
Furthermore, the DAPC has a signalling role, the loss of which also contributes to 41 
pathogenesis [4]. DMD patients are usually wheelchair-bound by the age of 12 and die of 42 
respiratory failure in their late teens or, with the help of respiratory support, in the 3
rd
 or 4
th
 43 
decade of life. Cardiac involvement is invariable, indicating that any therapeutic agent must 44 
also target the cardiac muscle. 45 
Noncoding RNAs (ncRNAs) have emerged as novel molecules that may be important in 46 
DMD [6]. ncRNAs can be sub-classified into three groups: housekeeping RNAs (ribosomal, 47 
transfer and splicesomal), long noncoding (pseudogenes, intronic and intergenic), and the 48 
small ncRNAs (piwi-associated RNA, endogenous short interfering RNA (siRNA) and 49 
microRNAs (miRNAs)). Of these, the miRNAs are the most studied in DMD. miRNAs are 50 
small RNAs, consisting of ~22 nts that are highly conserved across species and act as 51 
regulators of both genes and gene networks [7]. They are able to induce messenger RNA 52 
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(mRNA) degradation and/or inhibit mRNA translation, and as many as 60 % of mRNAs may 53 
be targets for miRNAs [8]. miRNAs control the signalling pathways in most cell types, have a 54 
role in development and cellular phenotype and regulate myogenic proliferation and fibrosis. 55 
Hence, miRNAs have been proposed to have a pathophysiological role in DMD. 56 
Furthermore, because miRNAs have been found to be extremely stable in serum, they may 57 
also be used as biomarkers to aid in the DMD diagnosis, as well as monitoring disease 58 
progression, and response to therapy. This review will focus on the association between 59 
miRNAs and DMD by reviewing the current knowledge (Table 1), and also reflect upon the 60 
lesser known, but also important lncRNAs. 61 
 62 
Human 63 
Eisenberg et al (2007) described 185 miRNAs that are up- or down-regulated in 10 major 64 
muscular disorders in humans (DMD, the milder allelic variant Becker muscular dystrophy, 65 
facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophies types 2A and 2B, 66 
Miyoshi myopathy, nemaline myopathy, polymyositis, dermatomyositis, and inclusion body 67 
myositis). Although five miRNAs were found to be consistently dysregulated in almost all 68 
muscle specimens analysed, pointing to possible involvement of a common regulatory 69 
mechanism, others were dysregulated only in one disease and not at all in the other disorders 70 
[9]. 29 miRNAs were increased in expression in DMD when compared to control patients 71 
(miR-21, -34a, -130a, -146b, -148, -154, -155, -199a, -199b, -210, -214, -221, -222, -299, -72 
335, -368, -376a, -379, -381, -432, -452, -487b, -495,-2537, -4983, -13145, and -13258), and 73 
2 significantly decreased in expression (miR-30a and -11040) [9]. Zaharieva et al (2013) 74 
furthered these studies, and demonstrated that miR-1, -133a,b and -206 were also upregulated 75 
in DMD, and that patients with low forced vital capacity (FVC) values, indicating respiratory 76 
muscle weakness, present with lower levels of serum miR-1 and -133b [10]. Further similar 77 
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studies [11–14], have suggested a panel of miRNAs including miR-1, -31, -133, -206, -208a,-78 
208b, and -499, that may be useful as biomarkers to diagnose patients, as well as profiling of 79 
different muscle cell phenotypes, including cardiac muscles, skeletal muscles, and vascular 80 
and visceral smooth muscles (miR-1, -133a, -145,-206, -208a, -208b, -499) [15]. Of course, 81 
ensuring that a standard SOP is followed by all such studies is vital to ensure the detection of 82 
“true” biomarkers. As such, the gold standard for miRNA detection methodology is RT-83 
qPCR and to normalize to a synthetic spike-in control oligonucleotide [16]. 84 
As well as acting as possible disease biomarkers, the targets for some of these miRNAs have 85 
also been described. For example, miR-21 and miR-29 play opposing roles in DMD muscle 86 
fibrosis, likely by targeting Collagen, Type III, Alpha 1 (COL3A1), Fibrillin 1 (FBN1) and 87 
YY1 Transcription Factor (YY1), either directly or indirectly [17]. Regulation of miR-199a-5p 88 
in a serum response factor (SRF)-dependent manner in human primary myoblasts and 89 
myotubes results in changes in cellular size, proliferation, and differentiation, via targeting of 90 
several myogenic cell proliferation and differentiation regulatory factors within the WNT 91 
signalling pathway, including Frizzled Class Receptor 4 (FZD4), Jagged 1 (JAG1), and 92 
Wingless-Type MMTV Integration Site Family Member 2 (WNT2) [18]. Differential Histone 93 
Deacetylase 2 (HDAC2) nitrosylation, observed in DMD when compared to non-disease 94 
controls deregulates miR-1, -29, and -206, which are linked to the G6PD enzyme, to 95 
extracellular proteins and the fibrotic process, and to muscle regeneration through repression 96 
of the satellite cell specific factor, Paired Box 7 (Pax7), in activated satellite cells [19]. 97 
Furthermore, Greco et al (2009) have recently identified miRNAs involved in the 98 
pathological pathways activated in skeletal muscle damage and regeneration triggered by a 99 
lack of dystrophin [20]. These DMD-signature miRNAs are divided into 3 classes. 1) 100 
Regeneration miRNAs (miR-31, -34c, -206, -335, -449, and -494) induced in DMD patients. 101 
2) Degenerative-miRNAs (miR-1, -29c, and -135a) down-modulated in DMD patients and 102 
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linked to myofiber loss and fibrosis. 3) Inflammatory miRNAs (miR-222 and -223), whose 103 
expression correlated with the presence of infiltrating inflammatory cells [20]. Inhibition of 104 
miR-486 in normal muscle myoblasts results in inhibited migration and failure to repair a 105 
wound in-vitro, and its overexpression results in increased proliferation, by regulating the 106 
phosphatase and tensin homolog deleted on chromosome 10/AKT (PTEN/AKT) pathway 107 
[21]. 108 
Interestingly, miRNAs may also be beneficial in improving exon skipping therapy in DMD 109 
patients. Cazzella et al (2012), has shown that the selection of U1 snRNA-antisense 110 
constructs to confer effective rescue of dystrophin synthesis in a ∆44 DMD genetic 111 
background, through skipping of exon 45. The restored dystrophin is able to recover the delay 112 
in myogenic marker expression in differentiating myoblasts, relocalise neuronal nitric oxide 113 
synthase (nNOS) and to rescue expression of miRNAs (including miR-1 and -29c) previously 114 
shown to be sensitive to the Dystrophin-nNOS-HDAC2 pathway [22]. Furthermore, miR-31 115 
represses dystrophin expression by targeting its 3' untranslated region, and in human DMD 116 
myoblasts treated with antisense oligonucleotides to induce exon skipping,  miR-31 inhibition 117 
increases dystrophin restoration, suggesting that modulating miR-31 expression may provide 118 
an additional strategy for those DMD therapies that are aimed at efficiently recovering 119 
dystrophin synthesis [23]. 120 
Other muscle specific miRNAs that are known to control both inflammation and proliferation 121 
in Airway Smooth Muscle (ASM), such as miR-145 [24], miR-150, -371-5p, -718, -940, -122 
1181, -1207-5p, -1915, -3663-3p [25], and miR-221 [26], may also prove important in DMD, 123 
but have yet to be studied. 124 
 125 
MDX mouse 126 
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There is a certain degree of overlap between miRNAs in human DMD and ‘naturally’ 127 
occurring animal models, suggesting evolutionary conservation of miRNA expression during 128 
DMD development. Indeed, Greco et al (2009) not only described the 3 classes of signature 129 
miRNAs (above), in human DMD, but also in MDX mice [20]. Furthermore, miR-1, -21, -29, 130 
-31, -133a, -148, -206, -222, and -335 are expressed in both species; however miR-29, -21 131 
and -148 are differentially expressed [27–36]. miR-23a, -30e, -34c, -193b, -223, -434, -449, 132 
and -494, as yet, remain unique to the MDX mice. The distribution of miRNAs in mouse 133 
muscle is better understood, compared to the human counterpart, with distinct patterns having 134 
been observed in the tibialis anterior (TA) muscle [31], diaphragm [37], heart [38], and the 135 
soleus and plantaris muscles in the leg [37]. miR-206 is particularly important in MDX mice, 136 
as it has been shown to be induced by fibro-adipogenic progenitors (FAPs), which are known 137 
to contribute to the pathogenesis and progression of DMD [39], as well as being modulated 138 
by mouse insulin-like growth factors (mIGF-1) [40]. The activity of miR-206 included both 139 
skeletal muscle regeneration [41], and differentiation of satellite cells via TNF Receptor-140 
Associated Factor 6, E3 Ubiquitin Protein Ligase (TRAF6) regulation [42]. miRNA targets 141 
are also better defined in the MDX model, with roles for the inhibition of dystrophin (miR-31, 142 
-146b and -374) [43] in Becker muscular dystrophy, improvement of disease progression via 143 
targeting of Dedicator Of Cytokinesis 3 (DOCK3) by miR-486 [44], downregulation of 144 
peroxisome proliferator-activated receptor γ1 (Pparγ1) by miR-27b [45], promotion of 145 
myogenic differentiation via miR-1, -133 and -102 targeting of BAF60 [46], and promotion of 146 
myofibroblast differentiation through the action of miR-29 targeting of Microfibrillar 147 
Associated Protein 5 (Mfap5) [47]. Recently, Israeli et al (2016), have reported upon the role 148 
of the above miRNAs (including miR-1, -21, -31, -133, -142-3p, -149-5p, -193b, -206, and -149 
378a-3p) for the evaluation of therapeutic outcome in medical approaches for numerous 150 
muscular dystrophies, including DMD [48]. 151 
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MDX mice are not the only mouse lineage to prove useful in our understanding of DMD. 152 
Indeed, the fact that extraocular muscles (EOM) are “spared” in advanced DMD [49], led to 153 
Zeiger and Khurana (2010), profiling the miRNA signature of EOM in WT mice, and 154 
discovering that miR-1, -133a and -133b are decreased in expression, and miR-206, is 155 
increased in expression, possibly explaining the differential sensitivity of this muscle allotype 156 
to dystrophin-deficiency [50]. Additionally, Ghahramani et al, (2010) preferred to knock-out 157 
dystrophin with RNAi in C57BL10 mice and study the transcriptome [51]. This approach, not 158 
only highlighted a change in expression of known miRNAs such as miR-208b, but also 159 
identified novel miRNAs including miR-128, -684 and -1192 [51]. Furthermore, mouse cell 160 
lines (i.e. C2C12) have proven useful in the study of DMD, to describe the posttranscriptional 161 
regulation of utrophin via miRNA targeting (let-7c, miR-133b, -150, -96b, -206, and -296) 162 
[52,53]. 163 
 164 
Canine and Ovine In-vivo Models 165 
Unlike the MDX mouse, which remains relatively normal (clinically), affected canine models 166 
of DMD develop progressive, fatal disease strikingly similar to the human condition. 167 
Accordingly, studies in the canine dystrophin-deficient models, such as golden retriever 168 
muscular dystrophy (GRMD) and canine X-linked muscular dystrophy in Japan dog model 169 
(CXMD(J)) may be more likely than those in MDX mice to predict pathogenesis and outcome 170 
of treatment in DMD. As yet, however, microRNA studies in these models are limited. Both 171 
miR-1 and -133a have been shown to be decreased in GRMD [54], and 9 miRNAs have been 172 
proposed to act as serum biomarkers (miR-1, -95, -133, -206, -208a, -208b, -378, -499, and -173 
539) [55]. Of these, two miRNAs (miR-208b and -539), have been shown to contribute to 174 
hypertrophy and the functional sparing of the cranial sartorius (SC) muscle [56]. Additional 175 
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studies in the Japanese CXMD(J), further highlight the importance of the microRNAs; miR-1, 176 
-133a and -206 [29]. 177 
Interestingly, two of the most frequently reported muscle miRNAs; miR-1 and -206, are 178 
proposed to target the 3'-UTR of the myostatin gene in the Texel sheep leading to inhibition 179 
of myostatin expression, which likely causes the muscular hypertrophy phenotype of this 180 
breed of sheep [57]. 181 
 182 
lncRNAs 183 
In addition to the miRNA family of short noncoding RNAs (< 200 nucleotides), there is now 184 
accumulating evidence that long noncoding RNAs (lncRNAs) with more than 200 185 
nucleotides can regulate multiple biological responses and that changes in their expression 186 
may be related to the development of disease [58,59]. For example, primary human airway 187 
smooth muscle (ASM) cell phenotype might, in part, be mediated through alterations in 188 
lncRNA expression [25], and targeting of the lncRNA, PVT1, has been demonstrated to 189 
control both the aberrant proliferation and inflammatory mediator release from ASM cells 190 
isolated  from patients with severe asthma [60]. Although studies on lncRNAs in DMD are 191 
limited, a handful of papers are starting to highlight the possible importance of these novel 192 
RNAs. 193 
For example, Ballarino et al, (2015) utilized a transcriptomic approach to identify novel 194 
lncRNAs in murine myoblast differentiation [61]. Furthermore, they demonstrated that lnc-31 195 
and its human homologue hsa-lnc-31 are expressed in proliferating myoblasts, where they 196 
counteract differentiation. This is not the only lncRNA to be commonly expressed in both 197 
mouse models and in humans, but linc-MD1 has been shown to be expressed during early 198 
stages of normal murine myoblast differentiation as well as human primary myoblasts from 199 
DMD patients [62], additionally its mechanism of action as a ‘sponge’ for miR-133b was 200 
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described by Twayana et al, (2013) [63]. Clearly, further studies are needed to delineate the 201 
role of these novel transcripts. 202 
  203 
Conclusion 204 
Recent studies indicate that ncRNAs may be important in diagnosing DMD, and in various 205 
aspects of its pathogenesis. However, although treatment of DMD, and other neuromuscular 206 
diseases currently involves oligonucleotide targeting (extensively reviewed in [64,65]), 207 
targeting of ncRNAs, or indeed, the effect of such therapies upon important ncRNAs remains 208 
to be seen. miRNAs (and to a lesser extent, currently, lncRNAs) appear to be important in all 209 
areas of DMD, and there is a potential for ncRNA research to uncover as yet unknown 210 
mechanisms in the pathogenesis DMD as well as being developed into novel therapies. 211 
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microRNA Function Target 
Human   
miR-21, miR-34a, miR-130a, miR-
146b, miR-148, miR-154, miR-155, 
miR-199a, miR-199b, miR-210, 
miR-214, miR-221, miR-222, miR-
299, miR-335, miR-368, miR-376a, 
miR-379, miR-381, miR-432, miR-
452, miR-487b, miR-495, miR-2537, 
miR-4983, miR-13145, miR-13258 
Increased in DMD muscle [9] 
 
? 
 
miR-30a, miR-11040 Decreased in DMD muscle [9] ? 
miR-1, miR-133b Decreased in DMD patients that had low FVC [10] ? 
miR-1, miR-31, miR-133, miR-206, 
miR-208a, miR-208b, miR-499 
Serum biomarker in patients [10–14] ? 
miR-1, miR-133a, miR-145, miR-
206, miR-208a, miR-208b, miR-499 
Profiling of muscle cells [15] 
 
? 
 
miR-21, miR-29 Reduced in DMD muscle and myoblasts [17] Likely: 
COL3A1, 
FBN1 and 
YY1 
miR-199a Dysregulated in dystrophin-deficient zebrafish, MDX 
mice, and DMD human muscle biopsies [18] 
FZD4, 
JAG1, and 
WNT2 
miR-1, miR-29, miR-206 Deregulated by HDAC2 nitrosylation [19] Pax7 
miR-1, miR-29, miR-135a Linked to myofiber loss and fibrosis [20] ? 
miR-1, miR-29 Recovery through exon 45 skipping [22] ? 
miR-486 
 
Regulates PTEN/AKT pathway in dystrophin-
deficient muscle [21] 
PTEN/AKT 
pathway 
miR-31 Represses dystrophin expression at 3’-end [23] Dystrophin 
MDX Mice   
miR-1, miR-23a, miR-29, miR-30e, 
miR-31, miR-34c, miR-133a, miR-
193b, miR-206, miR-222, miR-223, 
miR-335, miR-434, miR-449, miR-
494 
Increased in MDX mice [20,27–34] 
 
HDAC2, 
β1-
syntrophin 
 
 
miR-21, miR-143, miR-146a, miR-
148, miR-429, miR-451 
Decreased in MDX mice [34–36] ? 
miR-18a, miR-21, miR-34b, miR-
146b, miR-501, miR-675, miR-1983 
Increased in MDX mice TA muscle [31] ? 
miR-29c, miR-101b, miR-143, miR-
181a, miR-329, miR-337, miR-381, 
miR-434, miR-539 
Decreased in MDX mice TA muscle [31] ? 
miR-206 Increased in MDX mouse diaphragm [37] ? 
miR-448 Decreased in the hearts of MDX mice [38] Ncf1 
miR-133a Decreased in MDX mouse soleus and plantaris [37] ? 
miR-1, miR-133a, miR-145, miR-
206, miR-208a, miR-208b, miR-499 
Profiling of muscle cells [15] ? 
miR-199a 
 
Dysregulated in dystrophin-deficient zebrafish, MDX 
mice, and human muscle biopsies [18] 
FZD4, 
JAG1, and 
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WNT2 
miR-206 Induced by FAPs [39] ? 
miR-31, miR-146b, miR-374 Inhibits dystrophin [43] Dystrophin 
miR-486 Overexpression halts disease progression [44] DOCK3 
miR-1, miR-29, miR-135a Linked to myofiber loss and fibrosis [20] ? 
miR-24, miR-206 Modulated by mIGF-1 expression [40] ? 
miR-27b NO increased expression leading to downregulation 
of Pparγ1 expression [45] 
Pparγ1 
miR-1, miR-206 Promote differentiation of satellite cells [42] ? 
miR-1, miR-133, miR-102 Promotes myogenic differentiation [46] BAF60A, 
BAF60B 
miR-206 Promotes skeletal muscle regeneration [41] ? 
miR-21, miR-29 Reduced in DMD muscle and myoblasts [17] Likely: 
COL3A1, 
FBN1 and 
YY1 
miR-29 Regulated by TGF-β, and promotes myofibroblast 
differentiation [47] 
Mfap5 
miR-486 Regulates PTEN/AKT pathway in dystrophin-
deficient muscle [21] 
PTEN/AKT 
pathway 
WT Mice   
miR-206 Increased in EOM [50] ? 
miR-1, miR-133a, miR-133b Decreased in EOM [50] ? 
C57BL10 mice   
miR-128, miR-208b, miR-684, miR-
1192 
Dysregulated by dystrophin deficiency [51] ? 
C2C12 Mouse cell line   
miR-206, let-7c, miR-133b, miR-
150, miR-196b, miR-296 
Posttranscriptional regulation of utrophin [52,53] Utrophin 
GRMD   
miR-1, miR-133a Decreased in GRMD [54] ? 
miR-1, miR-95, miR-133, miR-206, 
miR-208a, miR-208b, miR-378, 
miR-499, miR-539 
Serum biomarker in GRMD [55] ? 
miR-208b, miR-539 Contributes to hypertrophy and functional sparing of 
the CS [56] 
? 
CXMD(J)   
miR-1, miR-133a, miR-206 Increased in CXMD(J) [29] ? 
Texel Sheep   
miR-1, miR-206 Causes muscular hypertrophy in Texel sheep [57] Myostatin 
Table 1. microRNAs and DMD 212 
Definition of abbreviations: FVC, forced vital capacity; COL3A1, Collagen, Type III, Alpha 213 
1; FBN1, Fibrillin 1; YY1, YY1 Transcription Factor; MDX, X chromosome-linked muscular 214 
dystrophy; FZD4, Frizzled Class Receptor 4; JAG1, Jagged 1; WNT2, Wingless-Type 215 
MMTV Integration Site Family Member 2; Pax7, Paired Box 7; HDAC2, Histone 216 
Deacetylase 2; PTEN, Phosphatase And Tensin Homolog; AKT, V-Akt Murine Thymoma 217 
Viral Oncogene Homolog; TA, Tibialis anterior; Ncf1, Neutrophil Cytosolic Factor 1; FAP, 218 
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Fibro-adipogenic progenitor; DOCK3, Dedicator Of Cytokinesis 3; mIFG1, mouse Insulin-219 
Like Growth Factor 1; NO, nitric oxide; Pparγ1, Peroxisome proliferator-activated receptor 220 
γ1; TGF, Transforming growth factor; EOM, extraocular muscle; GRMD, Golden retriever 221 
muscular dystrophy; CXMD(J), canine X-linked muscular dystrophy in Japan.  222 
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